In CRPC, the transcriptional addiction to the androgen receptor (AR, a ligand-activated transcription factor and main therapeutic target) seen in early-stage disease remains a major driver of tumour growth, but available androgen deprivation therapies, all of which effectively target the ligand binding domain of AR, fail to prevent disease progression [4]. This evidence concerns the gene AR and neoplasm.